socalTECH

JANUARY 18, 2011

and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.

Twiistup 145

Twiistup Avalon San Diego Conference 145

Xconomy

SEPTEMBER 27, 2016

San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. Bregua Corp.,

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Stengone said the new funding also will help the company evaluate the use of AVB-620 in other types of cancer surgery, to advance new cancer drugs that rely on Avelas’ proprietary technology, and to expand the company’s current roster of “seven employees and an army of consultants.”.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

AUGUST 31, 2016

In 2009, Tsien and Kevin Kinsella of Avalon Ventures founded San Diego’s Avelas Biosciences to develop fluorescent proteins that change color in the presence of cancer cells. In the statement released by UC San Diego, chancellor Pradeep Khosla said, every honor Tsien received was “justly deserved, and always received with humility.”.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

DECEMBER 7, 2018

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

Technology 98

Technology Develop Development San Diego 98

Xconomy

JULY 10, 2016

It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. In 1998, Nelsen recalled, “People thought we were crazy” to apply optics to genotyping when Affymetrix and its solid phase arrays represented the dominant technology at the time. They had a lot of fun.”.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

APRIL 30, 2018

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

Technology 78

Technology Venture Capital San Diego Avalon 78